iX Biopharma narrows losses in H1 FY 2026 despite 14% fall in revenue

Net loss narrowing to $2.1m, compared with a loss of $6.3m in 1H FY 2025.

iX Biopharma Ltd. reported improved earnings performance for the six months ended December 31, 2025, despite a year-on-year decline in revenue.

For the first half of FY 2026, the Group posted revenue of $3.2m, a 14% decrease from $3.7m recorded in the same period a year earlier.

The decline was offset by a significant reduction in losses, with net loss narrowing to $2.1m, compared with a loss of $6.3m in H1 FY 2025. Loss per share improved to $0.0023, from $0.0072 previously.

The Group’s balance sheet strengthened during the period, with total equity and net asset value rising to $4.1m, up sharply from $365,00p as of 30 June.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia